Osteoarthritis: OA continues to be one of the most commonly treated diseases in the United States, resulting in significant financial burden to both patients and healthcare systems. OA is a form of degenerative joint pain caused by progressive destruction within the joints. With the progression of OA, the cartilage, which acts to cushion joints, begins to be eroded, resulting in the destructive rubbing of bone-on-bone. The wear and tear leads to inflammation and pain of the joints. Despite years of clinical experience in treating OA, there remains to be a treatment that adequately alleviates pain, other than complete knee replacement.
Inflammation and pain:Adenosine is an adenine nucleoside that has been reported to be elevated during exercise and inflammation. Adenosine release at inflamed sites contributes to the erythema and resulting increased temperature at the site of inflammation. Experimentally, it was shown that at low adenosine concentrations, inflammation is exaggerated, leading to dramatic swelling, pain, increased blood flow, etc. Data has clearly shown the adenosine's anti-inflammatory actions results from activation of the extracellular adenosine A2A receptors on the vascular endothelium. These data suggest that adenosine, released at inflamed sites, diminishes the swelling that is so prominent at inflamed sites. Recent evidence has suggested that OA is an inflammatory/metabolic disease. Adenosine has been reported to have a bi-modal effect: at low concentrations adenosine acts via specific extracellular adenosine receptors to alleviate pain by acting as an anti-inflammatory agent, however, at relatively higher concentrations, different adenosine receptors are activated and induce pain by becoming cytotoxic. Several reports have suggested that adenosine and/or adenosine deaminase may be used as an early pre-clinical marker of arthritis.Hypothesis: During the early onset of OA, critical amounts of adenosine are released which act as anti-inflammatory agents. At these low concentrations of adenosine, the anti-inflammatory response is mediated via activation of the extracellular adenosine A2A receptor. Adenosine A1A receptor is also activated, which primarily decreases nerve conduction and metabolism, thereby acting as an anti-nociceptive mediator. Progression of AO leads to downregulation of A1A and A2A and activation of A2B receptors, which progressively increases the pain/inflammation and destruction of joints. Adenosine concentrations or extracellular adenosine receptor activation/deactivation may be early markers for assessing the progressive stage of OA.